Inclusion Criteria:
* Participant had a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis)
* Participants with moderate to severe RA defined as a Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 C-Reactive Protein (CRP) score \>3.2
* Biologically treatment naïve and initiated adalimumab at baseline visit, as per standard daily clinical practice
* Availability of clinical data of the previous 12 weeks prior to baseline
* Ability to self-complete participant questionnaires.
* Participants had signed the authorization (or informed consent where applicable) to disclose and use personal health information after having been prescribed adalimumab
Exclusion Criteria:
* Participants who were pregnant or breastfeeding at enrollment or wished to become pregnant in the next 24 weeks.
* Participation in any RA-related clinical trial at the time of enrollment, at baseline, or at any point during the past 24 weeks prior to baseline
* Participants, who in the clinician's view, may not have been able to accurately report their quality of life (QoL) or prior resource utilization
* Participants, who in the clinician's view, may not have been able to adhere to adalimumab therapy over 24 weeks
